Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity.
Zhang F, Schmidt F, Muecksch F, Wang Z, Gazumyan A, Nussenzweig MC, Gaebler C, Caskey M, Hatziioannou T, Bieniasz PD. Zhang F, et al. Among authors: caskey m. bioRxiv [Preprint]. 2023 Jun 30:2023.06.30.547241. doi: 10.1101/2023.06.30.547241. bioRxiv. 2023. PMID: 37425700 Free PMC article. Updated. Preprint.
Recommendations for measuring HIV reservoir size in cure-directed clinical trials.
Abdel-Mohsen M, Richman D, Siliciano RF, Nussenzweig MC, Howell BJ, Martinez-Picado J, Chomont N, Bar KJ, Yu XG, Lichterfeld M, Alcami J, Hazuda D, Bushman F, Siliciano JD, Betts MR, Spivak AM, Planelles V, Hahn BH, Smith DM, Ho YC, Buzon MJ, Gaebler C, Paiardini M, Li Q, Estes JD, Hope TJ, Kostman J, Mounzer K, Caskey M, Fox L, Frank I, Riley JL, Tebas P, Montaner LJ; BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection. Abdel-Mohsen M, et al. Among authors: caskey m. Nat Med. 2020 Sep;26(9):1339-1350. doi: 10.1038/s41591-020-1022-1. Epub 2020 Sep 7. Nat Med. 2020. PMID: 32895573 Free PMC article. Review.
Conserved Neutralizing Epitopes on the N-Terminal Domain of Variant SARS-CoV-2 Spike Proteins.
Wang Z, Muecksch F, Cho A, Gaebler C, Hoffmann HH, Ramos V, Zong S, Cipolla M, Johnson B, Schmidt F, DaSilva J, Bednarski E, Tanfous TB, Raspe R, Yao K, Lee YE, Chen T, Turroja M, Milard KG, Dizon J, Kaczynska A, Gazumyan A, Oliveira TY, Rice CM, Caskey M, Bieniasz PD, Hatziioannou T, Barnes CO, Nussenzweig MC. Wang Z, et al. Among authors: caskey m. bioRxiv [Preprint]. 2022 Feb 1:2022.02.01.478695. doi: 10.1101/2022.02.01.478695. bioRxiv. 2022. PMID: 35132412 Free PMC article. Updated. Preprint.
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 Trial.
Corado KC, Chew KW, Giganti MJ, Mu Y, Fletcher CV, Currier JS, Daar ES, Wohl DA, Li JZ, Moser CB, Ritz J, Javan AC, Neytman G, Caskey M, Hughes MD, Smith DM, Eron JJ; ACTIV-2/A5401 Study Team. Corado KC, et al. Among authors: caskey m. Pathog Immun. 2024 May 6;9(1):138-155. doi: 10.20411/pai.v9i1.660. eCollection 2024. Pathog Immun. 2024. PMID: 38746756 Free PMC article.
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV.
Mayer BT, Zhang L, deCamp AC, Yu C, Sato A, Angier H, Seaton KE, Yates N, Ledgerwood JE, Mayer K, Caskey M, Nussenzweig M, Stephenson K, Julg B, Barouch DH, Sobieszczyk ME, Edupuganti S, Kelley CF, McElrath MJ, Gelderblom HC, Pensiero M, McDermott A, Gama L, Koup RA, Gilbert PB, Cohen MS, Corey L, Hyrien O, Tomaras GD, Huang Y. Mayer BT, et al. Among authors: caskey m. Pharmaceutics. 2024 Apr 27;16(5):594. doi: 10.3390/pharmaceutics16050594. Pharmaceutics. 2024. PMID: 38794258 Free PMC article.
Transcription of HIV-1 at sites of intact latent provirus integration.
Teixeira AR, Bittar C, Silva Santos GS, Oliveira TY, Huang AS, Linden N, Ferreira IATM, Murdza T, Muecksch F, Jones RB, Caskey M, Jankovic M, Nussenzweig MC. Teixeira AR, et al. Among authors: caskey m. bioRxiv [Preprint]. 2024 Apr 29:2024.04.26.591331. doi: 10.1101/2024.04.26.591331. bioRxiv. 2024. PMID: 38746186 Free PMC article. Preprint.
Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.
Eron JJ, Little SJ, Crofoot G, Cook P, Ruane PJ, Jayaweera D, VanderVeen LA, DeJesus E, Zheng Y, Mills A, Huang H, Waldman SE, Ramgopal M, Gorgos L, Collins SE, Baeten JM, Caskey M. Eron JJ, et al. Among authors: caskey m. Lancet HIV. 2024 Mar;11(3):e146-e155. doi: 10.1016/S2352-3018(23)00293-X. Epub 2024 Jan 30. Lancet HIV. 2024. PMID: 38307098 Clinical Trial.
SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity.
Zhang F, Schmidt F, Muecksch F, Wang Z, Gazumyan A, Nussenzweig MC, Gaebler C, Caskey M, Hatziioannou T, Bieniasz PD. Zhang F, et al. Among authors: caskey m. mBio. 2024 Feb 14;15(2):e0167223. doi: 10.1128/mbio.01672-23. Epub 2024 Jan 9. mBio. 2024. PMID: 38193662 Free PMC article.
185 results